Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China

BACKGROUND: The health expenditure on treatment of advanced non-small cell lung cancer (NSCLC) is enormous, especially in third-line or further therapy. Cost-effectiveness analysis for the treatment of advanced NSCLC is particularly important. Anlotinib has been approved by the China Food and Drug A...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Qiuyan, Ni, Ronghua, Guan, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483086/
https://www.ncbi.nlm.nih.gov/pubmed/37691869
http://dx.doi.org/10.21037/tlcr-23-456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483086/
https://www.ncbi.nlm.nih.gov/pubmed/37691869
http://dx.doi.org/10.21037/tlcr-23-456

Ejemplares similares